DF/HCC Myeloid Malignancies SPORE - CEP & DRP RFAs

MARCH 17, 2020

The Myeloid Malignancies SPORE has released RFA's for its Career Enhancement and Developmental Research Project Awards, with applications due on May 1, 2020. Read more about these awards below for more information.

Career Enhancement Program RFA

The Leukemia Program at the Dana-Farber/Harvard Cancer Center (DF/HCC) is seeking applications for Career Enhancement Program (CEP) projects focused on adult or pediatric myeloid malignancies. Funding will be provided for up to two awards through the National Cancer Institute (NCI)-sponsored Specialized Program of Research Excellence (SPORE) mechanism.

 

REQUEST FOR APPLICATIONS: Career Enhancement Awards in Myeloid Malignancies
AWARD AMOUNT:

Up to two awards of up to $50,000 (direct cost) will be made for the funding period from August 1, 2020 through July 31, 2021.

APPLICATION DEADLINE: On or before 5pm on Friday, May 1, 2020

The Leukemia Program at the Dana-Farber/Harvard Cancer Center (DF/HCC) is seeking applications for Career Enhancement Program (CEP) projects focused on adult or pediatric myeloid malignancies. Funding will be provided for up to two awards through the National Cancer Institute (NCI)-sponsored Specialized Program of Research Excellence (SPORE) mechanism.

The goal of the CEP is to recruit and train new investigators in the field of translational myeloid malignancy research. Eligible candidates include Early Career Faculty (Instructor or Assistant Professor) without R01 or equivalent grants or senior post-doctoral fellows (PhD, MD, or MD-PhD) who have a written commitment from their department chair confirming plans for promotion to a faculty position within one year. Applicants must identify mentors (basic and clinical), provide a career development plan (may include didactic training), and propose a translational project (clinical or laboratory- based) with a human endpoint. Applications will be judged on: 1) the candidate’s academic track record, 2) the scientific merit of the research plan, 3) the likelihood that the proposed plan of mentored research and training will enhance the applicant’s development towards a career in independent translational myeloid malignancy research.

Application deadline is May 1, 2020 Up to two awards of up to $50,000 will be made for the funding period from August 1, 2020 through July 31, 2021. The grantee is expected to completely utilize the full amount by end of the funding period, and all unspent funds at the end of the grant period will be returned. Funds can be used for the applicants’ salary/fringe (up to 50% effort), research materials, travel, and didactic training at any DF/HCC-affiliated institution.

All Applications include (Arial 11 pt font):

  • Face Page

  • According to NIH Guidelines and Format: Budget & Justification (PHS 398 format), Biosketch, and Other Support

  • Career Development Plan (1 page maximum)

  • Research Plan (5 pages maximum, not including citations), includes:

    • Specific Aims

    • Significance to Myeloid Malignancy Research

    • Background and Preliminary Investigations

    • Experimental Design and Methods

    • Potential for Progressing to Full Scale Translational Studies

  • Mentor Letters of Support

  • If applicable: Copies of IRB and IACUC approvals, Letters of Support as described in instructions

Minority and women applicants are strongly encouraged to apply. Additional information may be obtained by contacting Dr. Dora Levin (JD_Levin@DFCI.HARVARD.EDU).

Hide

Developmental Research Project RFA

The Dana-Farber/Harvard Cancer Center Specialized Program in Research Excellence (SPORE) seeks applications for Developmental Research Project Awards in Myeloid Malignancies. The objective of the Developmental Research Program is to identify and fund new ideas and projects for the SPORE in Myeloid Malignancies.

 

REQUEST FOR APPLICATIONS: Developmental Research Project Awards in Myeloid Malignancies
AWARD AMOUNT:

We anticipate awarding 2 awards of up to $100,000 in annual direct costs.

APPLICATION DEADLINE: On or before 5pm on Friday, May 1, 2020


Download full RFA here 
Download Application Instructions here

The Dana-Farber/Harvard Cancer Center Specialized Program in Research Excellence (SPORE) seeks applications for Developmental Research Project Awards in Myeloid Malignancies. The objective of the Developmental Research Program is to identify and fund new ideas and projects for the SPORE in Myeloid Malignancies.

Applicants must be on the faculty at Harvard Medical School or the Harvard T.H. Chan School of Public Health at the level of Instructor or higher with an independent laboratory. A track record of interest and productivity in leukemia or hematologic malignancy research is strongly desired. The research plan and career goals of the individual may include the disciplines of basic biology, translational science, clinical science, population studies, outcomes, or social science but must have a future plan for translation into humans, since the purpose of this program is to promote translational research in Myeloid Malignancies. Applications will be judged on their merit and/or their potential contribution to the overall status of the DF/HCC SPORE in Myeloid Malignancies.

The awardees will receive one year of funding which can be used for salary and/or support of research at Harvard Medical School, the Harvard School of Public Health or any of the Harvard-affiliated hospitals. Awardees will be expected to attend SPORE activities (meetings, retreats, research presentations). Women and minority candidates are strongly encouraged to apply. We anticipate awarding 2 awards of up to $100,000 in annual direct costs. Project scope should be designed for completion within the funding period.

All Applications include (Arial 11 pt font):

  • Face Page

  • According to NIH Guidelines and Format: Budget & Justification (PHS 398 format), Biosketch, and Other Support

  • Research Plan (5 pages maximum, not including citations), includes:

    • SpecificAims

    • Significance to Myeloid Malignancy Research

    • Background and Preliminary Investigations

    • Experimental Design and Methods

    • Potential for Progressing to Full Scale Translational Studies

  • If applicable: IRB and IACUC approvals; LOS from sponsors, consultants or collaborators

Please forward a single PDF file containing all materials to Dr. Dora Levin (JD_Levin@DFCI.HARVARD.EDU) by May 1, 2020. Additional information may be obtained by contacting Dr. Dora Levin.

Hide